Indivior Pharmaceuticals Inc (FRA:E7P) Stock Price, Trades & News

Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).

Financial Strength

5/10

Name	Current	Vs Industry
Cash-To-Debt	0.34
Equity-to-Asset	-0.12
Debt-to-Equity	-3.54
Debt-to-EBITDA	1.44
Interest Coverage	8.38
Piotroski F-Score	4/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	3.7	Distress Grey Safe
Beneish M-Score	-0.83	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

5/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	14.3
	3-Year EPS without NRI Growth Rate	29.2
	3-Year FCF Growth Rate	-124.4
	Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank	17.32
	Future 3-5Y Total Revenue Growth Rate Estimate	3.52

Momentum Rank

1/10

	Name	Current	Vs Industry		Vs History
	5-Day RSI	59.13
	9-Day RSI	58.98
	14-Day RSI	59.02
	3-1 Month Momentum %	26.36
	6-1 Month Momentum %	11.64
	12-1 Month Momentum %	158.73

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	0.86
	Quick Ratio	0.66
	Cash Ratio	0.22
	Days Inventory	234.08
	Days Sales Outstanding	71.7
	Days Payable	66.36

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	3-Year Average Share Buyback Ratio	-65.6
	Shareholder Yield %	1.19

Profitability Rank

8/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	81.26
	Operating Margin %	25.95
	Net Margin %	19.44
	EBITDA Margin %	27.42
	FCF Margin %	-14.71
	OCF Margin %	-8.36
	ROE %	Neg. Equity
	ROA %	18.9
	ROIC %	47.08
	3-Year ROIIC %	-58.29
	ROC (Joel Greenblatt) %	210.16
	ROCE %	87.15
	Years of Profitability over Past 10-Year	7
	Moat Score	6
	Tariff Resilience Score	7

GF Value Rank

3/10

	Name	Current	Vs Industry		Vs History
	PE Ratio	20.77
	Forward PE Ratio	11.09
	PE Ratio without NRI	13.46
	Shiller PE Ratio	68.47
	PS Ratio	4.04
	EV-to-EBIT	15.29
	EV-to-Forward-EBIT	12.24
	EV-to-EBITDA	14.47
	EV-to-Forward-EBITDA	12.07
	EV-to-Revenue	3.97
	EV-to-Forward-Revenue	4.18
	EV-to-FCF	-26.54
	Price-to-GF-Value	1.79
	Price-to-Median-PS-Value	1.52
	Earnings Yield (Greenblatt) %	6.54
	FCF Yield %	-4.03
	Forward Rate of Return (Yacktman) %	-9.99

GF Value™: €19.63

FRA:E7P

Warning Signs

Warning! GuruFocus detected 3 Severe warning signs with E7P. Try a 7-Day Free Trial to check it out.

Indivior Pharmaceuticals Inc Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

Indivior Pharmaceuticals Inc Stock Events

Financials Calendars

Event	Date	Price (€)
Third quarter earnings conference call for 2026	2026-10-30 08:00	In 110 days
Third quarter earnings results for 2026	2026-10-30 07:00	In 110 days
Second quarter earnings conference call for 2026	2026-07-31 08:00	In 19 days
Second quarter earnings results for 2026	2026-07-31 07:00	In 19 days
General meeting for 2026	2026-05-13 10:00	33.60 (+3.07%)
General meeting for 2026	2026-05-08 12:00	33.80 (-0.59%)
First quarter earnings conference call for 2026	2026-04-30 08:00	29.40 (+2.08%)
First quarter earnings results for 2026	2026-04-30	29.40 (+2.08%)
First quarter earnings conference call for 2026	2026-04-24 08:00	28.20 (+0.71%)
First quarter earnings results for 2026	2026-04-24 02:00	28.20 (+0.71%)

Show

Entries

Press Release

	Subject	Date
	Indivior Announces Inclusion in the S&P SmallCap 600® Index	2025-12-22
	New Study Shows Extended-Release Buprenorphine Safely Delivers Rapid, Clinically Meaningful Reductions in Opioid Use and Supports Abstinence in High-Risk Populations	2025-12-17
	Indivior Concludes Legacy U.S. Department of Justice Matter	2025-11-20
	Indivior to Participate in the Piper Sandler 37th Annual Healthcare Conference	2025-11-19
	Indivior Presents New Real-World Evidence at AMCP Nexus 2025 Demonstrating Clinical and Economic Benefits of Adherence to Monthly Injectable Buprenorphine	2025-11-03
	Indivior Reports Third Quarter 2025 Financial Results and Raises Full-Year 2025 Financial Guidance	2025-10-30
	Indivior to Participate in the Stifel 2025 Healthcare Conference	2025-10-28
	Indivior to Report Third Quarter 2025 Financial Results and Host Webcast on October 30th	2025-10-16
	Clinical Evidence Supports Rapid SUBLOCADE® Induction as a Strategy to Improve Retention in Opioid Use Disorder Treatment	2025-10-15
	Indivior Proposes New Corporate Structure to Achieve U.S. Domiciliation	2025-10-01

10/Page

Articles on Indivior Pharmaceuticals Inc

No articles.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.